We focus on supplying world-leading treatments for patients in the Russian Federation who suffer from the rare disease, hemophilia. We follow strict guidelines as defined in Good Distribution Practice to ensure that our products are delivered safely, on time, and in compliance with the requirements of medicines which must be carefully handled and within defined temperature limits.
World Leading expertise
The company was established in 2016 and is a joint venture between Takeda Pharmaceuticals, a global company specializing in rare diseases, and Generium, a leading Russian Life Sciences company.
We are proud to work with Shire, a global leader in serving patients with rare diseases with treatments for hemophilia. In partnership with Takeda, we work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them.